Tourniquet Use in Anterior Cruciate Ligament Repair
Launched by ORTHOCAROLINA RESEARCH INSTITUTE, INC. · Jun 27, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Type of Study Double-blinded randomized controlled clinical trial
Group 1 (Control): Patients undergoing patellar bone-tendon-bone autograft ACL reconstruction with a tourniquet used for the duration of the case.
Group 2 (Treatment/Intervention, if applicable): Patients undergoing ACL reconstruction with a tourniquet used only during patellar bone-tendon-bone autograft harvest, for a maximum of 20 minutes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing an arthroscopic assisted ACLR using a bone-tendon-bone patellar tendon autograft.
- • 2. 18 years or older
- • 3. English speaking
- Exclusion Criteria:
- • 1. Concomitant procedures (e.g., osteotomy or other ligamentous reconstructions) other than chondroplasty, partial meniscectomy or meniscal repair
- • 2. Medical contraindications to epinephrine or TXA use.
- • 3. Hemophilia or other predisposition for bleeding
- • 4. Does not follow study protocol in regard to regional anesthesia, TXA, epinephrine use in the arthroscopy fluid and post-operative rehabilitation.
- • 5. Participation in physical therapy at any facility other than the OrthoCarolina Randolph, Matthews or South Park locations
About Orthocarolina Research Institute, Inc.
Orthocarolina Research Institute, Inc. is a leading clinical research organization dedicated to advancing orthopedic care through innovative research and clinical trials. With a focus on improving patient outcomes, the institute collaborates with a network of healthcare professionals to conduct rigorous studies that explore new treatments and technologies in orthopedics. Committed to ethical standards and scientific integrity, Orthocarolina Research Institute aims to enhance the understanding of musculoskeletal conditions, ultimately contributing to the development of evidence-based practices and improving the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlotte, North Carolina, United States
Patients applied
Trial Officials
Jonathan Riboh, MD
Principal Investigator
OrthoCarolina Research Institute, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported